Generate Biomedicines, Inc. (GENB) SEC filings
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.07−0.50 (-3.98%)
Close on Nov 13, 2026Market cap $1.55BP/E –Yield –
SEC filings
8 of Generate Biomedicines's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Nov 12, 2026 | Nov 12, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2026 | Nov 12, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 25, 2026 | Aug 26, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 6, 2026 | Aug 6, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 6, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 7, 2026 | SEC EDGAR |
| Current report | 8-K | May 7, 2026 | May 7, 2026 | SEC EDGAR |
| Current report | 8-K | Feb 26, 2026 | Mar 2, 2026 | SEC EDGAR |
See a number that looks wrong?